

# CORZYNA™

(ranolazine 500 mg extended-release tablets)

## CORZYNA™ Purchase Support Program

For patients who do not have prescription drug coverage, KYE is pleased to announce an enhanced CORZYNA™ Purchase Support Program (PSP) in conjunction with our partner PHARMEX Direct Inc. that will provide an initial 30-days of therapy with CORZYNA™ 500 mg tablets at no cost to your uninsured patients.

The 30-day trial is a one-time offer for uninsured cash-paying patients who are newly enrolled in the PSP. Once the trial has ended, and together you have decided the benefits of continued therapy with CORZYNA™ have been demonstrated, the patient will simply need to start purchasing the product through the PSP at a significantly reduced cost of therapy.

### To enroll patients in the CORZYNA™ Purchase Support Program, the steps are:

1. Physicians must phone (1-800-663-8637) or fax (905-847-8271) a prescription for CORZYNA™ 500 mg to PHARMEX Direct.
2. Patients must register with PHARMEX Direct by phoning 1-800-663-8637 or visiting [www.pharmexdirect.com/enroll](http://www.pharmexdirect.com/enroll).
3. A one-time 30-day supply of CORZYNA™ 500 mg will be delivered to the patient at no cost.
4. PHARMEX Direct will contact patients 7 days before the end of the trial to inquire if they will continue or discontinue therapy through the PSP.
5. If patients choose to continue therapy with CORZYNA™, they will receive supply at a 45% or greater discount to the regular price, depending on total daily dosage. The PSP price excludes shipping fees which are waived with a purchase of a 3-month supply.

For more information on CORZYNA™ or to book a call with your local representative please visit [www.kyepharma.com](http://www.kyepharma.com) or email [CORZYNA@kyepharma.com](mailto:CORZYNA@kyepharma.com).

CORZYNA™ (ranolazine extended-release tablets) is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.<sup>1</sup>



1. CORZYNA™ Product Monograph (current), KYE Pharmaceuticals Inc.